Patients with bronchiectasis in China have a high disease burden and a low rate of use of evidence-based treatments.
Macrolide maintenance therapy in patients with bronchiectasis significantly reduces the risk for major adverse cardiovascular events.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback